This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Effect of cognitive training on the expression of brain-derived neurotrophic factor in lymphocytes of mild cognitive impairment patients
Casoli, Tiziana,
Giuli, Cinzia,
Balietti, Marta,
Giorgetti, Belinda,
Solazzi, Moreno,
Fattoretti, Patrizia
To identify biomarkers associated with cognitive stimulation of mild cognitive impairment (MCI) patients, we performed quantitative real-time reverse transcriptase polymerase chain reaction for brain-derived neurotrophic factor (BDNF) mRNA in peripheral lymphocytes of MCI and healthy subjects undergoing a multi-component cognitive training (CT) program. CT determined a significant decrease of BDNF mRNA levels in MCI (fold […]
Evidence for neurocognitive plasticity in at-risk older adults: the experience corps program
Carlson, M. C.,
Erickson, K. I.,
Kramer, A. F.,
Voss, M. W.,
Bolea, N.,
Mielke, M.,
McGill, S.,
Rebok, G. W.,
Seeman, T.,
Fried, L. P.
Objective: To determine whether Experience Corps (EC), a social service program, would improve age-vulnerable executive functions and increase activity in brain regions in a high-risk group through increased cognitive and physical activity.; Methods: Eight community-dwelling, older female volunteers and nine matched wait-list controls were recruited to serve in the ongoing EC: Baltimore program in three […]
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, Aaron H,
Grimes, Imogene,
Galasko, Douglas R,
Aisen, Paul S,
Sabbagh, Marwan,
Mjalli, Adnan MM
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]
Promoting health in early-stage dementia: evaluation of a 12-week course
This project tested a 12-week health promotion course for older adults with early-stage dementia. In a quasi-experimental design, participants were assigned by site to intervention group or control group and evaluated at two time points. Mini-Mental State Examination scores, Geriatric Depression Scale scores, health behaviors, plus several measures of psychological well-being were used in this […]
Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates
Bondi, Mark W.,
Edmonds, Emily C.,
Jak, Amy J.,
Clark, Lindsay R.,
Delano-Wood, Lisa,
McDonald, Carrie R.,
Nation, Daniel A.,
Libon, David J.,
Au, Rhoda,
Galasko, Douglas,
Salmon, David P.
We compared two methods of diagnosing mild cognitive impairment (MCI): conventional Petersen/Winblad criteria as operationalized by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and an actuarial neuropsychological method put forward by Jak and Bondi designed to balance sensitivity and reliability. 1,150 ADNI participants were diagnosed at baseline as cognitively normal (CN) or MCI via ADNI criteria […]
Yogic meditation reverses NF-κB and IRF-related transcriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial
Black, David S.,
Cole, Steve W.,
Irwin, Michael R.,
Breen, Elizabeth,
St. Cyr, Natalie M.,
Nazarian, Nora,
Khalsa, Dharma S.,
Lavretsky, Helen
Background: Although yoga and meditation have been used for stress reduction with reported improvement in inflammation, little is known about the biological mechanisms mediating such effects. The present study examined if a yogic meditation might alter the activity of inflammatory and antiviral transcription control pathways that shape immune cell gene expression. Methods: Forty-five family dementia […]
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, Leigh J.,
Adams, William H.,
Langbehn, Douglas,
Fiedorowicz, Jess G.,
Jorge, Ricardo,
Biglan, Kevin,
Caviness, John,
Olson, Blair,
Robinson, Robert G.,
Kieburtz, Karl,
Paulsen, Jane S.
Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]